MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aimed to Improve Patient Responses to Immunotherapies
Lyon, France, April 8, 2024, 7:20 p.m. CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), an advanced clinical-stage biotechnology company, leader in the development of Microbiome Ecosystem TherapiesTM (MET) aimed at improving patient survival with cancers, presents at the 2024 annual conference of the American Association for Cancer Research (AACR) in San Diego, California, new in vitro data characterizing the metabolites produced by MaaT034 and their impacts on immune modulation .
To receive all financial information from MaaT Pharma in real time and for any questions, you can contact us via the following address: [email protected]